Clinical Trial Detail

NCT ID NCT02597036
Title A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

Advanced Solid Tumor

hepatocellular carcinoma

gastroesophageal junction adenocarcinoma

gastric adenocarcinoma

Therapies

LY3127804

Ramucirumab

Age Groups: adult

No variant requirements are available.